Correlation Between Gilead Sciences and Halozyme Therapeutics

Can any of the company-specific risk be diversified away by investing in both Gilead Sciences and Halozyme Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Gilead Sciences and Halozyme Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Gilead Sciences and Halozyme Therapeutics, you can compare the effects of market volatilities on Gilead Sciences and Halozyme Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Gilead Sciences with a short position of Halozyme Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Gilead Sciences and Halozyme Therapeutics.

Diversification Opportunities for Gilead Sciences and Halozyme Therapeutics

-0.43

Correlation Coefficient

Gilead Sciences  Halozyme Therapeutics

Very good diversification

The 3 months correlation between Gilead and Halozyme is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding Gilead Sciences and Halozyme Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Halozyme Therapeutics and Gilead Sciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Gilead Sciences are associated (or correlated) with Halozyme Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Halozyme Therapeutics has no effect on the direction of Gilead Sciences i.e., Gilead Sciences and Halozyme Therapeutics go up and down completely randomly.

Pair Corralation between Gilead Sciences and Halozyme Therapeutics

Given the investment horizon of 90 days Gilead Sciences is expected to generate 0.37 times more return on investment than Halozyme Therapeutics. However, Gilead Sciences is 2.68 times less risky than Halozyme Therapeutics. It trades about 0.18 of its potential returns per unit of risk. Halozyme Therapeutics is currently generating about -0.08 per unit of risk. If you would invest  7,896  in Gilead Sciences on September 2, 2024 and sell it today you would earn a total of  1,362  from holding Gilead Sciences or generate 17.25% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Gilead Sciences  vs.  Halozyme Therapeutics

Gilead Sciences

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Gilead Sciences are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating essential indicators, Gilead Sciences exhibited solid returns over the last few months and may actually be approaching a breakup point.

Halozyme Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Halozyme Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Gilead Sciences and Halozyme Therapeutics

The main advantage of trading using opposite Gilead Sciences and Halozyme Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Gilead Sciences position performs unexpectedly, Halozyme Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will offset losses from the drop in Halozyme Therapeutics' long position.

The idea behind Gilead Sciences and Halozyme Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.